3 recruiting, 2 terminated, 2 withdrawn, 1 active not recruiting. 10 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Recruiting 3, Terminated 2, Withdrawn 2, Active not recruiting 1, Completed 1, Unknown 1 |
| Phase 1 | 3 | Active not recruiting 1, Recruiting 1, Terminated 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Ischemia Reperfusion Injury: new trials by email Literature Review of Ischemia Reperfusion Injury trials Research Report on Ischemia Reperfusion Injury
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of BX-001N in Preventing Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI) and Major Adverse Kidney Events (MAKE) BX-001N Experimental group 1, BX-001N Experimental group 2, Placebo group 1 - Ischemia Reperfusion Injury, Cardiac Surgery Associated - Acute Kidney Injury | Phase 2 | Recruiting | Bilix Co.,Ltd. | 50 | 2025-08-26 | 2026-07-01 |
| Hypertonic Lactate After Cardiac Arrest Sodium Lactate Solution - Cardiac Arrest, Ischemia Reperfusion Injury | Phase 2 | Recruiting | Erasme University Hospital | 125 | 2025-02-19 | 2025-02-21 |
| Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Liver Transplant Patients Valproic acid, Isotonic saline solution - Acute Kidney Injury, Ischemia Reperfusion Injury | Phase 2 | Withdrawn | Westat | 2022-01-01 | 2021-10-29 | |
| Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Trauma Patients Valproic Acid Solution, Isotonic saline solution - Acute Kidney Injury, Ischemia Reperfusion Injury | Phase 2 | Withdrawn | Westat | 2022-01-01 | 2021-10-29 | |
| NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial Niacinamide, Placebo - Ischemia Reperfusion Injury, Myocardial Injury | Phase 2 | Completed | Kaiser Permanente | 331 | 2021-09-13 | 2026-10-26 |
| Safety and Efficacy of Treprostinil (Remodulin®) In Reducing Ischemia-Reperfusion Injury During Kidney Transplantation Treprostinil - Ischemia Reperfusion Injury, Delayed Graft Function | Phase 1 / Phase 2 | Recruiting | Rhode Island Hospital | 20 | 2020-11-13 | 2026-04-23 |
| Intravenous Estrogen in Kidney Transplant Study Conjugated Estrogen, Normal saline - Ischemia Reperfusion Injury | Phase 1 / Phase 2 | Active not recruiting | University of Pennsylvania | 30 | 2016-08-26 | 2026-04-16 |
| Effects of Intravenous Bendavia™ on Reperfusion Injury in Patients Undergoing Angioplasty of the Renal Artery Bendavia, Placebo - Renal Artery Obstruction, Hypertension, Renovascular | Phase 1 / Phase 2 | Terminated | Stealth BioTherapeutics Inc. | 16 | 2012-12-01 | 2020-08-11 |
| TOP-Study (Tacrolimus Organ Perfusion): Treatment of Ischemia Reperfusion Injury in Marginal Organs With an ex Vivo Tacrolimus Perfusion Tacrolimus, HTK/Placebo - Terminal Liver Disease, Ischemia Reperfusion Injury | Phase 2 / Phase 3 | Terminated | Ludwig-Maximilians - University of Munich | 25 | 2011-10-01 | 2017-03-23 |
| YSPSL for Prevention of Ischemic Reperfusion Injury in Patients Undergoing Cadaveric Orthotopic Liver Transplantation recombinant P-selectin glycoprotein ligand Ig fusion protein, Viaspan® and saline - Ischemia Reperfusion Injury | Phase 2 | Unknown | Y's Therapeutics, Inc. | 36 | 2008-05-01 | 2009-04-07 |
Reperfusion Injury (10) · Acute Kidney Injury (3) · Hemorrhage (2) · Delayed Graft Function (1) · Heart Arrest (1) · Hypertension, Renovascular (1) · Hypoxia-Ischemia, Brain (1) · Renal Artery Obstruction (1) · Wounds and Injuries (1)
Cardiovascular Diseases (10) · Pathologic Processes (10) · Pathological Conditions, Signs and Symptoms (10) · Postoperative Complications (10) · Vascular Diseases (10) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Kidney Diseases (4) · Male Urogenital Diseases (4) · Urogenital Diseases (4) · Urologic Diseases (4) · Renal Insufficiency (3) · Arterial Occlusive Diseases (1) · Brain Diseases (1) · Brain Ischemia (1)
Saline Solution (2) · Sodium Chloride (2) · Valproic Acid (2) · Estrogens, Conjugated (USP) (1) · Niacinamide (1) · Receptor, EphB4 (1) · Tacrolimus (1) · University of Wisconsin-lactobionate solution (1) · arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide (1) · treprostinil (1)
Westat (2) · Bilix Co.,Ltd. (1) · Erasme University Hospital (1) · Kaiser Permanente (1) · Ludwig-Maximilians - University of Munich (1) · Rhode Island Hospital (1) · Stealth BioTherapeutics Inc. (1) · University of Pennsylvania (1) · Y's Therapeutics, Inc. (1)
United States (7) · Belgium (1) · Germany (1) · South Korea (1)
Cristina Rabadan-Diehl, PharmD, PhD (2) · Filippo Annoni, MD (1) · Karl-Walter Jauch, M.D. (1) · Martin Angele, M.D. (1) · Matthew Levine, MD, PhD (1) · Myung Lip Kim, Chief Executive Officer (1) · Richard Straube, MD (1) · Sebastian Pratschke, M.D. (1) · Stefan Hemmerich, PhD (1) · Stephen C Textor, MD (1)
PMID 10231466, PMID 12219027, PMID 12234307, PMID 12389082, PMID 15251365, PMID 15358759, PMID 15618244, PMID 15670785, PMID 15698835, PMID 17336333, PMID 1963650, PMID 19638737, PMID 21274961, PMID 21398592, PMID 21401865, PMID 21658244, PMID 21691090, PMID 22572084, PMID 23497558, PMID 23552495, PMID 27088798, PMID 27500266, PMID 2850395, PMID 28916603, PMID 3018561, PMID 38689404, PMID 6281704, PMID 9112349